9am-5pm EST | 3pm-11pm CET

8:00 am Morning Networking Coffee


Grab a quick cup of tea or coffee from the comfort of your own home office and start chatting with your peers in a virtual coffee room.

8:45 am Chair’s Opening Remarks

Does the Choice of Novel Targeted Therapies Best Tailored to the Needs of Patients?

9:00 am Strategies for Overcoming the Immunosuppressive Prostate Tumor Microenvironment

  • Sumit Subudhi Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, University of Texas, MD Anderson Cancer Center


• Take a look at immunologically “cold” tumor with low tumor mutational burden and few T cells
• Examine limited efficacy of monotherapies with immune checkpoint blockade
• Discover primary and adaptive resistance mechanisms to immune checkpoint blockade
• Assess approaches to overcome resistance mechanisms

9:30 am Advance the Development of an Epigenetic-based Therapy in Castration-Resistant Prostate Cancer (CRPC)

  • Eric Campeau Senior Director of Translational Medicine, Zenith Epigenetics


• Explore the combination of the BET bromodomain inhibitor ZEN-3694 with enzalutamide: updated results from the Phase 2a trial
• Discover mechanisms of resistance to enzalutamide targeted by ZEN-3694
• Examine translational data informing patient pre-selection strategy

10:00 am Investigating CD3 Bispecific Treatment of Solid Tumors using PSMAxCD3

  • Alison Crawford Associate Director of Immuno-Oncology, Regeneron Pharmaceuticals, Inc


• Examine generation of a mouse expressing human CD3 and PSMA
• Evaluate pre-clinical efficacy data using PSMAxCD3 monotherapy
• Investigate combinations with PSMAxCD3

10:30 am Morning Break & Virtual Speed Networking


Grab a quick cup of tea or coffee from the comfort of your own kitchen and jump straight into your opportunity to connect with new contacts from active companies in the field and exchange virtual business cards. Form lasting connections through this exclusive virtual speed networking!

11:00 am Optimize Radiopharmaceuticals: Therapy Updates & Development in Prostate Cancer

  • Oliver Sartor Professor of Medicine Medical Director, Tulane Cancer Center & Bernadine Laborde Professor of Cancer Research


• Overview of lingards
• Discuss isotopes
• Evaluate clinical data
• Understand the challenges in clinical trial design

11:30 am Spotlight on Veyonda®: Is Noxopharm’s Veyonda the Answer to Safe & Effective Prostate Cancer Treatment?


• Examine recently released data showing a mOS of 19.7 months in late-stage prostate cancer in a trial combining Veyonda® with a Novartis radiopharmaceutical LuPSMA-617
• Discover the IONIC study to test the ability of Veyonda® to overcome cancer tumours’ resistance to the immune checkpoint inhibitor, nivolumab (BMS’ Opdivo®) in a range of solid cancers
• Explore Noxopharm’s DARRT regimen combines Veyonda® with lowdose radiotherapy which is applied to a single secondary tumour in the treatment of mCRPC
• Evaluate how the DARRT-2 Phase 2 multinational study will further test this treatment in late-stage cancers such as prostate cancer in a larger group of patients

12:00 pm Bringing Theranostics to Prostate Cancer: A patient centered, safe, and efficient pharmacotherapy


• Integrate therapeutic nuclear medicine with diagnostics in the development of new prostate cancer therapies
• Discover how theranostic strategies can be integrated into existing prostate cancer management strategies
• Design new studies using with PSMA targeting agents in prostate cancer

12:30 pm Networking Lunch


• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

1:30 pm Beyond BRCA: Biomarkers of DNA Damage Response Deficiency (DDR-D)

  • Patrick Pilié Assistant Professor GU Medical Oncology, MD Anderson Cancer Center


• Discuss the current landscape of predictive and prognostic DDR-D biomarkers
• Examine functional biomarkers of DDR-D in development
• Evaluate targeting of replication stress response in prostate cancer and associated DDR-D biomarkers

2:00 pm PSMA-ATAC: Introducing a Novel Mode of Action into Prostate Cancer Therapy


  • Antibody Targeted Amanitin Conjugates (ATACs) represent a new class of ADCs using the payload Amanitin with a novel mode of action (inhibition of RNA polymerase II)
  • Discuss how the unique MoA facilitates the killing of dormant tumor cells and offers new treatment options for difficult to treat cancers
  • Explore the predictive biomarker for ATACs, del(17p), which also identifies high-risk patients in many cancer indications
  • Examine the PSMA-targeting ATAC that is under development for prostate cancer

Stronger together:
Navigating Through the Plethora of Combinatorial Therapies

2:30 pm Chemotherapy & Chemotherapy Combinations – Is there Still a Role in Prostate Cancer?

  • Ana Aparicio Associate Professor & Director Clinical Research Group, University of Texas, MD Anderson Cancer Center


• Understand the definition of ‘chemotherapy’
• Overview of clinical data in support of chemotherapies in use for prostate cancer
• Explore mechanism of action in the context of prostate cancer biology
• Discuss the biological rationale for combinations with novel agents

3:00 pm Afternoon Break


• Live Demo in Virtual Exhibition Hall
• 1-1 Meetings

3:30 pm Targeting Treatment Emergent Genomic Alterations & Tumor Plasticity


• Overview of treatment emergent variants including AR independent CRPC and small cell neuroendocrine prostate cancer
• Target tumor plasticity and other therapeutic opportunities in treatment resistant disease
• Examine clinical trial considerations

4:00 pm Panel Discussion: Evaluate the Current Challenges, Approaches & Opportunities in Treating Prostate Cancer

  • Ramesh Narayanan Professor of the Department of Medicine & Director of Center for Cancer Drug Discovery, University of Tennessee Health Science Center
  • Alessandra Cesano Chief Medical Officer, ESSA Pharmaceuticals
  • Graham Kelly Chief Executive Officer & Founder, Noxopharm
  • Vivek Arora Director, Translational Medicine,Early Clinical Development, Hematology/ Oncology & Cell Therapy, Bristol-Myers Squibb (BMS)


• What have we learnt?
• How do we overcome the crowded space of overtreatment?
• How can drug developers cut to the real barriers, and debate what is truly required to break through to successful treatments for prostate cancer?
• Discuss the impact of COVID-19 and its repercussions on existing clinical trials

4:45 pm Chair Closing Remarks